Medical technology company Monivent reports minor changes in its results for the second quarter while the company approaches MDR approval ahead of the planned launch with Dräger.Net sales increased to SEK 0,3 million (0,2).Operating result was SEK -2,6 million (-2,1).During the quarter, Monivent carried out a directed share issue that provided the company with SEK 10,4 million after issue costs, as well as a set-off issue for a bridge loan of SEK 8,0 million excluding interest. In addition, warrants were issued that become exercisable upon MDR approval and which, if fully exercised, could provide an additional SEK 10-15 million.CEO Maria Lindqvist states that, if the warrants perform well, the plan is for the capital to finance the company until positive cash flow at the end of 2028.Monivent states that the process for MDR approval is progressing according to the previously communicated timetable. After the end of the quarter, the notified body BSI announced that it currently has no further questions. A final review remains.The company continues to expect to obtain MDR approval and begin the launch of Neo100 in Europe together with Dräger during the second half of the year.However, the plan to have the FDA 510(k) application ready before the end of the second quarter has been delayed after the need for supplementary information was identified. The application is now planned to be submitted during the coming months."We have an important product that fills a clear gap in the market and we will now, with great commitment, through valuable partnerships and thanks to strong support from both new and existing shareholders, ensure that our products reach an increasing number of customers and patients worldwide," Lindqvist concludes in her CEO statement.Key figures, SEK millionQ2 2026Q2 2025Year-over-year changeNet sales0,30,262,1%Operating result-2,6-2,1